US Patent and Trademark Office issues patent to Lineage Cell Therapeutics covering Proprietary manufacturing and differentiation process for RPE Cells


The patent covers the company’s development of this cell transplant therapy as a treatment for geographic atrophy.

©Olivier Le Moal /

(Image Credit: ©Olivier Le Moal -

Lineage Cell Therapeutics, Inc. has received U.S. Patent No. 11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells” issued by the United States Patent and Trademark Office (USPTO). This patent is expected to expire on July 28, 2036. Until this time or unless it is otherwise liscened, the patent is exclusively licensed to Lineage.

In the news release, the company shared that the patent is issued for RG6501 (OpRegen®), a suspension of human allogeneic RPE cells currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This treatment involves a subretinal delivery of OpRegen, which has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function. The treatment program is being developed under an exclusive worldwide collaboration between Lineage, Roche, and Genentech, a member of the Roche Group.

According to the press release, Lineage Cell Therapeutics CEO, Brian M. Culley said that this shows the company’s ability to further new treatment programs. He is quoted as saying, “This U.S. patent further enhances the value of our lead program, OpRegen, which is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD (NCT05626114). Importantly, Lineage is continuing to demonstrate its ability to benefit from decades of experience in the growth and differentiation of pluripotent cells, while simultaneously inventing and patenting new process development methods, to support long periods of exclusivity to our pipeline of cell transplant programs.”

  1. Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells. Lineage Cell Therapeutics, Inc. October 11, 2023. Accessed October 12, 2023.
Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
EURETINA 2022: Leadership discusses what to expect, outlines Women in Retina program
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
© 2024 MJH Life Sciences

All rights reserved.